InnoSIGN
The explosion of omics data, especially from high-throughput RNA sequencing, has transformed the biomedical research landscape. However, this overwhelming amount of data has also created a bottleneck-- researchers and clinicians are now inundated with complex datasets that are challenging to interpret and translate into actionable insights. InnoSIGN, a Philips Research spin out, addresses this critical need through its flagship product, Comprehensive Pathway Analysis (CPA). CPA bridges the gap between raw RNA data and by delivering a visual roadmap of functional signaling activity. This platform holds profound implications for pharmaceutical research, drug discovery, and precision medicine, particularly in patient stratification and treatment response prediction across a wide range of disease areas.Content by InnoSIGN
| 2 min read
Collaboration combines Scipher’s unique RNAseq data with InnoSIGN’s proprietary comprehensive pathway analysis (CPA) platform to enhance the understanding of complex immune-mediated diseases.
Page 1 of 1 - 1 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Reliable fluid biomarkers strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Understanding drug impurities: types, sources, and analytical strategies
Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Discovering cutting-edge nitrosamine analysis in pharmaceuticals
New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
